Dr. Fauci: You’ll ‘get into trouble’ if you’re not up to date on COVID vaccines and boosters — here are 3 stocks that could get a shot in the arm

Dr. Fauci: You’ll be ‘in trouble’ if you’re not up-to-date on Covid vaccines and boosters – here are 3 stocks that could get a shot in the arm

With the summer travel season in full swing, the COVID-19 pandemic may seem like a thing of the past.

But if you don’t stay up-to-date on your vaccines and boosters, the consequences can be dire, says President Biden’s chief medical adviser, Dr. Anthony Fauci said.

“If they’re not vaccinated or they’re not boosted, they’re going to be in trouble,” Dr. Fauci told KNX News 97.1 — a Los Angeles radio station — earlier this week.

He noted that vaccine and booster rates in the US were “absolutely dismal”.

According to the Kaiser Family Foundation, 228 million Americans (or 70% of the US population) were not up to date on COVID-19 vaccines as of July 20, 2022. Staying “up to date” on vaccines means getting the primary series. and at least one booster dose.

Dr. It’s hard to say whether Fauci’s warning will lead to more Americans getting the COVID-19 vaccine and booster shots. But it gives investors reason to check the companies that make those vaccines.

Don’t miss it

modern (mRNA)

Currently, the most dominant strain of Covid in the US is Omicron’s BA.5 subvariant. And Moderna can help the country fight it.

Earlier this week, the company’s CEO Stefan Bansel told Yahoo Finance that they are “working really hard” to create a launch-specific booster this fall.

“We are already making the BA.4/5 vaccine as we speak,” he says. “We will provide more data as we get closer to it, but we know how important it is. And know the importance of each day.”

In Q2, Moderna generated $4.7 billion in total revenue, up from $4.4 billion a year ago. Management attributed the top-line growth to higher sales of the company’s Covid-19 vaccine product.

But Moderna shares are not Immunity to Market Sale this year. In 2022 they are down to about 20%.

Piper Sandler analyst Edward Tenthoff has an ‘overweight’ rating on Moderna and a price target of $214 — roughly 14% above where the stock sits today.

Biotech (BNTX)

Biotech is another big name in the Covid vaccine business.

According to Statista, more than 355,396,322 doses of the Pfizer-BioNTech COVID-19 vaccine had been administered in the US as of July 20 — more than any vaccine made by any other manufacturer.

On June 25, Pfizer and BioNTech announced that their Omicron-modified vaccine candidates had shown high immune responses against Omicron.

It also hopes to tackle new subvariants.

“Preliminary laboratory studies show that both Omicron-optimized candidates neutralize Omicron BA.4 and BA.5 although to a lesser extent than they do for BA.1,” the companies said, adding that they are “collecting additional study data on Omicron BA.4 are.” /BA.5.”

The biotech will report Q2 earnings before the bell on Monday, August 8.

Earlier, management said it expected the biotech’s Covid-19 vaccine revenue to come in between €13 billion and €17 billion for the full year 2022.

Last month, SVB Securities analyst Diana Grebosch upgraded BioNTech to ‘outperform’ from ‘market perform’. Her $233 price target on the shares suggests a potential upside of 28%.

Novavax (NVAX)

Novavax is a new name to consider when it comes to Covid vaccine stocks.

Last month, the US Food and Drug Administration granted emergency use approval for the Novavax COVID-19 vaccine adjuvanted (NVX-CoV2373). In a critical phase 3 clinical trial, the two-dose vaccine was 90.4% effective in preventing mild, moderate, or severe COVID-19.

Novavax President and CEO Stanley C. “This approval demonstrates the strength of our COVID-19 vaccine’s efficacy and safety data and underscores the critical need to provide another vaccine option for the U.S. population as the pandemic continues,” said Erk. A press release.

Novavax shares, however, have been pummeled – it’s down an astonishing 57% year to date.

B. Relay Securities analyst Mayank Mamtani sees a comeback on the horizon. He has a buy rating on Novavax and a price target of $171.

Given that Novavax currently trades at around $60 per share, Mamtani’s price target is suggestive. Potential upside of 185%.

What to read next

  • Sign up To get a steady stream for our Moneywise investment newsletter Actionable ideas From Wall Street’s top firms.

  • The US is just days away from going ‘full blast’ on inflation — here it is 3 shockproof sectors To help protect your portfolio

  • ‘There’s always a bull market somewhere’: Jim Cramer’s famous words imply that you can make money no matter what. Here are 2 A powerful tailwind To take advantage of today

This article provides information only and should not be construed as advice. This is provided without warranty of any kind.

Source link

Leave a Comment